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ABSTRACT 
Background: Staphylococcus aureus is an important pathogen in paediatric patients 
with bloodstream infections. The epidemiology of S. aureus bacteraemia (SAB), 
however, has not been well documented in children in South Africa.  
Methods: A retrospective study was conducted at a children’s hospital in Cape Town, 
South Africa, to investigate the epidemiology of SAB from 2007-2011. The incidence, 
clinical presentation, risk factors, management and outcomes of methicillin sensitive S. 
aureus (MSSA) and methicillin resistant S. aureus (MRSA) bacteraemia were 
compared. 
Results: Over the five year study period, 365 episodes of SAB were identified. The 
annual incidence of SAB was 3.28 cases per 1000 hospital admissions. MRSA was 
responsible for 26% of SAB and 72% of nosocomial infections. Only six possible cases 
of community-acquired MRSA infections were described. MSSA bacteraemia was more 
likely to present as pulmonary and bone or joint infections, while bacteraemia without a 
source was the most common presentation with MRSA.  Infants, children with 
malnutrition, and residents of long-term care facilities were at highest risk for MRSA 
bacteraemia. The overall case fatality rate for SAB was 8.8% over five years, with 
MRSA being the only significant risk factor for mortality.  
Conclusion: The incidence of SAB and MRSA bacteraemia in children has remained 
stable over the past five years. MRSA is a predominantly nosocomial pathogen in 
children with SAB in Cape Town, South Africa.   
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PART A: STUDY PROTOCOL 
Epidemiology of Staphylococcus aureus bacteraemia at a tertiary 
children’s hospital in Cape Town, South Africa 
Investigator:  Reené Naidoo1 
Supervisors: Brian Eley1 and James Nuttall1 
Collaborator: Andrew Whitelaw2 
1 Paediatric Infectious Diseases Unit, Red Cross War Memorial Children’s Hospital and 
the School of Child and Adolescent Health, University of Cape Town, South Africa 
2 National Health Laboratory Services, Groote Schuur Hospital, University of Cape 
Town, South Africa 
 
INTRODUCTION 
Staphylococcus aureus is a ubiquitous gram-positive bacterium known to colonize the 
skin and mucous membranes of healthy individuals, with primary sites being the anterior 
nares, the axilla, perineum and rectum. It is also a major human pathogen capable of 
causing a wide variety of infections ranging from skin and soft tissue infections to life-
threatening invasive disease. This highly adaptive organism has become a significant 
source of nosocomial and community-acquired infections worldwide.  
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Methicillin resistant S. aureus (MRSA) was first described in 1961, soon after the 
introduction of anti-staphylococcal penicillins (Zetola et al., 2005). Methicillin resistance 
is conferred by a penicillin-binding protein, PBP2A, encoded by the mecA gene located 
on the staphylococcal cassette chromosome (SCC) mec. PBP2A allows bacterial cell 
wall biosynthesis despite the presence of beta-lactam antibiotics (Bassetti et al., 2009).   
 
Traditionally, MRSA has been associated with healthcare-associated infections. Specific 
risk factors for healthcare-associated infection include hospitalization or surgery within 
one year of infection, recent out-patient hospital visit, residence in a long-term care 
facility, recent antibiotic exposure, chronic illness or close contact with a person with 
any of these risk factors (Aires de Sousa & de Lencastre, 2004; Bassetti et al., 2009). 
Since the late 1990’s, however, community-acquired MRSA infections have been 
rapidly emerging (Aires de Sousa & de Lencastre, 2004). Community-acquired MRSA 
(CA-MRSA) is distinguished from healthcare-associated MRSA (HA-MRSA) by the 
absence of any of the aforementioned risk factors, a distinct antimicrobial sensitivity 
pattern and a different genetic background.  In contrast to HA-MRSA, which is generally 
multi-drug resistant, CA-MRSA has been noted to be susceptible to multiple non-beta-
lactam antibiotics such as clindamycin, fluoroquinolones, gentamicin, trimethoprim-
sulfamethoxazole, and rifampicin. Molecular genetic typing has also shown that HA-
MRSA possesses unique SCCmec types I-III, whereas CA-MRSA carries SCCmec 
types IV and V and also the gene for the unique Panton-Valentine leukocidin exotoxin 
(Bassetti et al., 2009).  
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The incidence of infections caused by S. aureus and MRSA in particular, has been 
increasing rapidly throughout the world.  A recent international multi-centre study 
reported rates of MRSA in South Africa as high as 39% (Zinn et al., 2004). In addition, 
the Pan-European Antimicrobial Resistance Using Local Surveillance (PEARLS) study, 
conducted in 17 different countries, showed a MRSA rate of 33% in South Africa, which 
was comparable to the mean worldwide incidence of 32% (Bouchillon et al., 2004). 
Local studies conducted in Johannesburg and KwaZulu-Natal, showed rates of MRSA 
of 23% and 27% respectively (Perovic et al., 2006; Shittu & Lin, 2006).  
 
The antimicrobial resistance patterns of S. aureus differ significantly based on whether 
the strain is healthcare-associated or community-acquired. A recent study investigating 
the antimicrobial sensitivity of MRSA isolates throughout South Africa showed high 
rates of resistance to non-beta-lactam antibiotics, with most isolates being multi-drug 
resistant (Marais et al., 2009). Notably, differing antibiotic profiles were recorded 
between the public and private health care systems. Significantly higher rates of 
antibiotic resistance to rifampicin, gentamicin and trimethoprim-sulfamethoxazole were 
noted in the public sector, while higher rates of resistance to ciprofloxacin, clindamycin 
and erythromycin were noted in the private health sector. These different resistance 
patterns were attributed to variation in disease profiles and empirical antibiotic choices 
amongst clinicians in the public and private sectors. 
 
The majority of studies on S. aureus in South Africa were conducted on both adults and 
children. Few local studies have characterized S. aureus infections in children alone.  A 
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recent study on community-acquired pneumonia at Red Cross Children’s Hospital 
showed that S. aureus was one of the predominant pathogens isolated from upper and 
lower respiratory tract secretions in children with pneumonia, especially in those who 
were HIV positive (Zar et al., 2003). A similar study, conducted at Chris Hani 
Baragwanath Hospital in Johannesburg in children with lower respiratory tract 
infections, revealed that 60% of S. aureus isolates in HIV-infected children were MRSA 
(Madhi et al., 2000).  
 
Clinical experience at Red Cross Children’s Hospital suggests that the incidence of 
MRSA is low but there is no recent evidence to support this conclusion. Studies, 
showing MRSA rates of between 23% and 39% in large tertiary hospitals in South 
Africa, suggest that a detailed investigation of S. aureus infections in children at our 
institution is warranted.   
 
AIM 
To investigate the epidemiology of S. aureus bacteraemia in children at Red Cross 
Children’s Hospital.  
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OBJECTIVES 
1. To determine the rate of S. aureus bacteraemia per 1000 hospital admissions per 
year at Red Cross Children’s Hospital over a 5 year period from January 2007 to 
December 2011. 
a. To determine the frequency of MRSA bacteraemia per year over the 5 year 
period. 
b. To determine the frequency of  MSSA bacteraemia  per year over the 5 year 
period 
2. To compare the clinical presentations of  MSSA and MRSA bacteraemia , 
3. To investigate the antibiotic sensitivity profiles of  S. aureus bacteraemia isolates , 
and to describe current management at Red Cross Children’s Hospital with regard to 
antibiotic choice, time to effective antibiotic therapy and duration of treatment,  
4. To characterize the temperature patterns of children with  S. aureus bacteraemia 
5. To compare the clinical outcomes of patients with invasive MSSA and MRSA 
infections.  
 
METHODS 
Setting 
The study will be undertaken at Red Cross Children’s Hospital in Cape Town, South 
Africa. This is a tertiary level children’s hospital serving all children up to the age of 13 
years. It serves as a major referral centre in the Western Cape province of South Africa. 
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Study design 
The study will be a retrospective review of all paediatric patients seen at Red Cross 
Children’s Hospital with culture-confirmed S. aureus bacteraemia between January 
2007 and December 2011. The National Health Laboratory Service (NHLS) 
microbiology database will be used to identify S. aureus blood culture isolates over the 
study period. Patient clinical records will be retrospectively examined and data collected 
on demographic information, diagnosis, onset of infection, site of infection, underlying 
illnesses, potential risk factors for HA-MRSA, antibiotic susceptibility profiles and clinical 
outcomes.  
 
Definitions 
1. S. aureus bacteraemia is defined as the isolation of S. aureus from a blood culture 
specimen. 
2. The isolation of S. aureus from a blood culture drawn more than 48 hours after 
admission to hospital, or drawn at readmission within 48 hours of discharge, was 
considered to be a nosocomial infection. Healthcare-associated infections were 
defined as those that occurred within 48 hours of admission to hospital, with at least 
one of the following healthcare-associated risk factors: hospitalization or surgery 
within one year of onset of infection, presence of an invasive device at the time of 
admission, resident of a long-term care facility, and history of MRSA colonization or 
infection. Community-acquired infections were those identified within 48 hours of 
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hospital admission, but with none of the aforementioned healthcare-associated risk 
factors (Klevens et al., 2007). 
3. HIV infection is determined by HIV PCR testing in children younger than 18 months 
of age and by HIV ELISA testing in children over 18 months of age.   
4. Malnutrition according to WHO growth standards is defined as a weight-for-height or 
height-for-age z-score between -2 to -3 SD below the mean NCHS/WHO reference 
values for moderate malnutrition, while severe malnutrition is defined as a weight-
for-height or height-for-age z score below -3SD of the mean, or by the presence of 
nutritional oedema (WHO, 1999). 
 
Statistical analysis 
Data will be analysed with standard statistical procedures. Analysis of variance 
(ANOVA) and unpaired t-tests will be used to analyse parametric variables. Non-
parametric variables will be assessed with Mann Whitney or Kruskal Wallis tests. 
Categorical variables will be assessed with chi-square tests.  
 
Ethical considerations 
This study will be undertaken as a retrospective chart review. All records will be treated 
confidentially by the investigator.  The study will be submitted for approval to the 
Departmental Research Committee, Department of Child and Adolescent Health, 
University of Cape Town, and the Research Ethics Committee of the Faculty of Health 
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Sciences, University of Cape Town. The study will be done in accordance with the 
Declaration of Helsinki (SA DoH, 2006). 
 
The study poses no risks or direct benefits to the study participants as the investigation 
is retrospective.  The anticipated benefit of this investigation is to contribute to scientific 
knowledge of S. aureus infections in a local context and facilitate clinical patient 
management.  
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PART B: LITERATURE REVIEW 
INTRODUCTION 
Bloodstream infections are an important cause of serious and potentially life-threatening 
disease in children. Staphylococcus aureus is a common gram positive organism 
responsible for community and hospital-acquired infections in both adults and children. 
Worldwide, the spectrum of this highly adaptive organism has bee  changing rapidly 
over time. Within 30 years of the discovery of penicillin in the 1920’s, penicillin-resistant 
S. aureus became pandemic, and strikingly, within 3 years after the introduction of 
semi-synthetic penicillin, methicillin-resistant S. aureus (MRSA) was first reported in 
England in 1961 (DeLeo & Chambers, 2009; Zetola et al., 2005). Since then, MRSA has 
become a dominant cause of nosocomial infections in hospitals throughout the world. In 
the early 1990’s, however, the first report of community-acquired MRSA infections arose 
and again, these new strains of S. aureus have been reported globally (Bassetti et al., 
2009).  
 
While S. aureus infections in children have been described in many developed 
countries, the epidemiology is not well defined in South Africa. In order to improve our 
understanding and clinical management of this infection, it is vital to define the burden 
of disease locally. This literature review was conducted to establish the relative 
contribution of S. aureus to bloodstream infections in children in South Africa and in 
Africa as a whole, and secondly to evaluate the epidemiology of S. aureus bacteraemia 
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(SAB) in paediatric patients with regard to incidence, clinical presentation, risk factors, 
antimicrobial susceptibility patterns, clinical management and disease outcome. 
 
LITERATURE RESEARCH STRATEGY 
This literature search was conducted between November 2009 and June 2012 utilizing 
PubMed, with search terms “bacteraemia” and “Africa” in order to contextualize the 
contribution of SAB to all causes of bacteraemia in children in African countries. A 
second search was then performed with PubMed using the search terms 
“Staphylococcus aureus” and “bacteraemia”. In both search strategies, the studies were 
limited to those conducted in children under the age of 18 years and included original 
research, meta-analysis and review articles. Case reports were excluded from analysis. 
Additional articles were accessed with citation tracking from original work. Certain 
studies containing both adult and paediatric data were included if they pertained to the 
epidemiology of S. aureus infections in South Africa.  
 
SUMMARY AND INTERPRETATION OF LITERATURE 
Frequency of S. aureus as a cause of bacteraemia in Africa 
Few South African studies have investigated the relative contribution of S. aureus to 
bacteraemia in paediatric patients. Cotton et al. (1992) described SAB to account for 
11.6% of community and hospital-acquired bacteraemia in 165 children at a single 
tertiary hospital in Cape Town, while Berkowitz (1984) described an SAB rate of 6% 
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amongst 315 nosocomial cases of bacteraemia.  Most other studies in South Africa 
were conducted on HIV-infected children. In 3 separate studies, SAB was reported to be 
responsible for 10.6%, 11% and 15.7% of bacteraemia in HIV-infected children (Cotton 
et al., 2008; Jaspan et al., 2008; Le Roux et al., 2011). 
 
Bacteraemia in children has been more extensively investigated in other African 
countries compared to South Africa, although changes in the trends of bloodstream 
infections over time have not been well identified. Overall, a meta-analysis of 
community-acquired bloodstream infections identified SAB to be responsible for 12% of 
bacteraemia in children in Africa (Reddy et al., 2010). The frequency of SAB, however, 
varied greatly according to geographical region. In Malawi, only 1.9% of community-
acquired bacteraemia were  attributed to SAB (Walsh et al., 2000) while SAB rates of 7-
9% were noted in Rwanda, Zimbabwe and Kenya (Lepage et al., 1987; Nathoo et al., 
1996; Berkley et al., 2005; Brent et al., 2006). A higher SAB rate of 18.3% was 
described in Gambia and 20.9% in Nigeria (Hill et al., 2007; Obaro et al., 2011). Studies 
that have included both hospital and community-acquired bacteraemia, found an overall 
SAB rate of 12.5% in Kenya with 83% of these being community-acquired, 9% 
healthcare-associated and 8% nosocomial in origin (Aiken et al., 2011). Comparable 
findings were described in Tanzania, with SAB accounting for 10.2% of all bacteraemia, 
although in this study, 43% of SAB were community-acquired and 57% hospital-
acquired (Blomberg et al., 2007). A single study conducted in Nigeria reported that SAB 
accounted for 48.7% of community and hospital-acquired bacteraemia (Meremikwu et 
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al., 2005). This high rate, however, was attributed to the high proportion of neonates 
included in this study.    
 
Frequency of S. aureus bacteraemia 
The epidemiology of SAB in children in South Africa has not been well described. A 
study conducted at Red Cross War Memorial Children’s Hospital in 1974, reported on S. 
aureus infections in paediatric patients (Davis & White, 1974). This study included all S. 
aureus infections and was not specific to bacteraemia. At that time, 2% of isolates were 
reported to be MRSA. A second study, focusing on endocarditis in 36 children with SAB 
in Johannesburg, noted an MRSA rate of 31% (Friedland et al., 1995). No studies 
reported on the epidemiology of SAB and MRSA bacteraemia in South Africa from 1995 
until 2004, when two international multi-centre studies reported rates of MRSA of 
33.3%-39% in South Africa (Zinn et al., 2004; Bouchillion et al., 2004). This high rate of 
MRSA was further confirmed when a study from KwaZulu-Natal noted MRSA rates of 
26.9% (Shittu & Lin, 2006). More recently, a national surveillance study on antimicrobial 
susceptibility revealed that 30-60% of S. aureus isolates in the South African public 
health sector were methicillin-resistant (Bamford et al., 2011). Most of these 
epidemiological studies included both adult and paediatric patients and do not provide 
an accurate quantification of MRSA in children in South Africa.  
 
Studies in other African countries reported relatively low rates of MRSA in children. 
Three studies that investigated community-acquired SAB in Nigeria and Gambia 
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reported no MRSA isolates (Meremiku et al., 2005; Hill et al., 2007; Obaro et al., 2011). 
In Kenya, only 1% of SAB isolates were identified as MRSA, even though 10% of the 
SAB infections were nosocomial in origin (Ladhani et al., 2004). Only in Mozambique 
was there a report of a higher incidence of MRSA (8%) in children less than 15 years of 
age (Mandomando et al., 2010).  A meta-analysis of community-acquired bacteraemia 
in adults and children in Africa found that 14% of SAB isolates were methicillin-resistant, 
but only 35 of 531 S. aureus isolates were tested for methicillin resistance in 22 different 
studies (Reddy et al., 2010). This systematic review appears to suggest that lack of 
detection rather than absence of disease may account for the low reported rate of 
MRSA bacteraemia.  
 
Internationally, SAB has been extensively described. Three countries have conducted 
population based studies in children; in New Zealand the incidence of SAB was 16.9 per 
100 000 population between 1996 and 1998 (Hill et al., 2001); in Denmark rates of SAB 
increased from 4.6 per 100 000 in 1971 to 8.4 per 100 000 population in 2000 
(Frederiksen et al., 2007); in Calgary, Canada, SAB rates of 5.9 per 100 000 were 
reported between 2000 and 2006 (Vanderkooi et al., 2011). Most other investigations 
have reported the incidence of SAB within individual hospital settings; 3.7 cases per 
1000 hospital admissions in California, USA (Burke et al., 2009), and 1.13 cases per 
1000 paediatric admissions in Sydney, Australia (Suryati & Watson, 2002). MRSA rates 
as a proportion of SAB vary widely depending on geographical location. Denmark and 
Canada reported a very low frequency of 1% and 0.8% respectively (Frederiksen et al., 
2007; Vanderkooi et al., 2011) compared to 6% in New Zealand and 14% in Australia 
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(Hill et al., 2001; Suryati & Watson, 2002). Data from the United Kingdom is variable. A 
surveillance study of MRSA bacteraemia in children noted an incidence rate of 1.1 per 
100 000 child population per year between 2005 and 2007 (Johnson et al., 2010). 
Khairulddin et al. (2004) reported MRSA in England and Wales to have increased from 
0.9% in 1990 to 13% in 2000, while Denniston & Riordan (2006) reported stable rates of 
MRSA of 5.8% in children and 27% in neonates at a single institution from 1993-2003. 
Adedeji and Gray (2005) also reported a stable rate of 15% between 1998 and 2003 at 
a single children’s hospital. Rates of MRSA in the United States, however, have been 
increasing steadily over time. Wisplinghoff et al. (2003) reported MRSA bacteraemia to 
have increased from 10% in 1995 to 29% in 2001 in 49 paediatric hospitals throughout 
the country, while Burke et al. (2009) reported a similar increase of 9% in 2001 to 24% 
in 2006 in California. 
 
Community-acquired MRSA (CA-MRSA) strains were first identified in Western 
Australia in 1993 and have been reported to be increasing throughout the world (Aires 
de Sousa & de Lencastre, 2004). CA-MRSA has been defined as MRSA infection 
acquired in the community or isolated within 48 hours after admission to hospital in 
patients without any healthcare-associated risk factors such as (1) previous 
hospitalization, dialysis or surgery within one year, (2) indwelling medical device at the 
time of admission, (3) resident of a long term care facility within one year or (4) history 
of MRSA colonization or infection (Klevens et al., 2007).  CA-MRSA is postulated to 
have originated de novo in the community rather than spread from the hospital 
environment, as it has been described to have distinct genotypes and specific 
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antimicrobial susceptibility profiles (Shinefield & Ruff, 2009). Traditionally, the 
staphylococcal cassette chromosome (SCC) mec types IV and V, and strains producing 
the Panton-Valentine leukocidin toxin, have been associated with CA-MRSA isolates.  
However, recent evidence has shown that these molecular distinctions are becoming 
less clear (David et al., 2011). Most episodes of CA-MRSA are related to skin and soft 
tissue infections (Bassetti et al., 2009). CA-MRSA bacteraemia in children was reported 
to represent 4.7% of all invasive CA-MRSA infections in Taiwan (Chen et al., 2007), and 
2.5%, 4.2% and 4.7% of all community-acquired S. aureus infections in children in 
Illinois, New York and Texas respectively (Sattler et al., 2002; Mongkolrattanothai et al., 
2009; Suryadevara et al., 2010). Two South African studies have documented cases of 
CA-MRSA locally; one investigating MRSA isolates in both adults and children in Cape 
Town, identified 10 of 100 specimens to be CA-MRSA based on epidemiological criteria 
(Jansen van Rensburg et al., 2011) while an adult study on S. aureus bacteraemia 
reported 20% of their study population to have acquired MRSA in the community 
(Perovic et al., 2006). No other country in Africa has reported CA-MRSA in children. 
 
Source of infection and clinical presentation 
Both MSSA and MRSA bacteraemia are causes of nosocomial infection. In Australia, 
the United Kingdom and the United States, 47-52% of SAB infections were nosocomial 
in origin (Suryati & Watson, 2002; Denniston & Riordan, 2006; Burke et al., 2009). In 
contrast, only 10% of SAB in Kenya were hospital-acquired infections (Ladhani et al., 
2004). This may be attributed to the high rates of co-morbid illnesses and hence 
hospital-exposure in children in the Australian, United Kingdom and United States-
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based studies, compared to those in the Kenyan cohort. Hospital-acquired SAB 
occurred more commonly in children less than 1 year of age (Hill et al., 2001; 
Frederiksen et al., 2005). Suryati & Watson (2002) in Australia and Burke et al. (2009) 
in the United States found that MRSA contributed approximately 26% of nosocomial 
SAB. 
 
The most frequent clinical diagnoses at the time of SAB were bacteraemia without 
focus, bone or joint infections, skin or soft tissue infections (SSTI) and respiratory tract 
infections. No focus of infection was detected in a third to a half of all SAB cases 
(Suryati & Watson, 2002; Ladhani et al., 2004; Denniston & Riordan, 2006). The 
incidence of endocarditis was low; 1.4% in Australia (Suryati & Watson, 2002), 1.7% in 
Denmark (Vanderkooi et al., 2011) and 1.3% in the USA (Burke et al., 2009).  Notably, 
routine echocardiography was not perf rmed in these studies. The findings of a 
paediatric study in South Africa, however, is cause for concern as it found clinically 
silent endocarditis in 11% of children hospitalized with SAB (Friedland et al., 1995). 
None of the children had clinical signs of endocarditis and only one had underlying 
congenital cardiac disease. Although the sample size was small with only 36 children 
being evaluated in the study, it does raise the question of whether echocardiography 
should be conducted routinely in children with SAB. 
 
Only one study evaluated the response of infective markers and temperature to SAB 
infections (Suryati & Watson, 2002). Notably, 30% of patients with SAB did not mount a 
leucocytosis response to the infection, while 24% did not present with fever. This 
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absence of clinical and laboratory markers of infection would make the prediction of 
bacteraemia more difficult. Additionally, the presence of a focus of infection did not 
affect either temperature or white cell count responses.  
 
Risk factors for SAB and MRSA 
Malnutrition has been shown to be a significant risk factor for bacteraemia in children in 
South Africa, Kenya and Malawi (Cotton et al., 1992; Friedland, 1992; Norton et al., 
2004; Berkley et al., 2005; Aiken et al., 2011). Only one study, however, evaluated 
malnutrition as a specific risk factor for SAB. Ladhani et al. (2004) reported SAB without 
focus, to occur more frequently in children with malnutrition in Kenya.  
 
HIV infection has also been shown to be associated with bacteraemia in children in 
Africa (Nathoo et al., 1996; Berkley et al., 2005). The link between HIV infection and 
SAB specifically has not been described, although HIV-infected children were noted to 
be at higher risk for MRSA infections; 77%-100% of SAB were due to MRSA 
bacteraemia in HIV-infected children (Cotton et al., 2008; Jaspan et al., 2008; Le Roux 
et al., 2011). This is likely due to the higher risk of hospitalization in HIV-infected 
children and consequently an increased risk of hospital-acquired infections.  
 
 Generally, infants appear to have a higher incidence of SAB compared to older children 
(Hill et al., 2001; Suryati & Watson, 2002; Adedeji & Gray, 2005; Denniston & Riordan, 
2006; Frederiksen et al., 2007; Burke et al., 2009). Infants may also be at higher risk of 
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MRSA bacteraemia, as described in England and Wales (Khairulddin et al., 2004). 
Several studies also described SAB as occurring more commonly in those with co-
morbid conditions, such as congenital heart disease, malignancy and chronic skin 
disorders (Denniston & Riordan, 2006; Burke et al., 2009; Vanderkooi et al., 2011). With 
regard to MRSA infection, intravascular devices, most commonly central venous 
catheters, were the most commonly identified risk factor. Indwelling devices were 
responsible for 63% of MRSA infections in children and 88% in neonates in England 
(Adedeji & Gray, 2005; Denniston & Riordan, 2006). An Australian study, however, 
noted an equal incidence of MSSA and MRSA infections in children with central line 
infections due to SAB (Suryati & Watson, 2002).   
 
Antimicrobial sensitivities 
Several South African studies investigated antimicrobial susceptibility patterns for S. 
aureus in both adult and paediatric patients. With the exception of widespread 
resistance to penicillin (92%), most MSSA isolates were susceptible to the majority of 
antibiotics against which they were tested (Shittu & Lin, 2006). MRSA, however, 
displayed multi-drug resistance patterns with over 75% of isolates in KZN, and 55-78% 
of isolates nationally, being resistant to gentamicin, trimethoprim-sulfamethoxazole 
(TMP/SMX), erythromycin and clindamycin (Shittu & Lin, 2006; Marais et al., 
2009).Susceptibility patterns of ciprofloxacin and rifampicin differed in the two studies; 
69% versus 18% for ciprofloxacin and 38% versus 74% for rifampicin in the national and 
the KZN study, respectively. This may be attributed to the inclusion of both public and 
private sector MRSA isolates in the national study which demonstrated differing 
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antimicrobial susceptibility profiles between patients in these two sectors (Marais et al., 
2009). Isolates from the private sector were more likely to be resistant to the commonly 
used antibiotics ciprofloxacin, clindamycin and erythromycin, while public sector patients 
were more likely to be infected with isolates that were resistant to gentamicin, rifampicin 
and TMP/SMX.  In the public health service, gentamicin is a standard first line 
antimicrobial agent for the management of sepsis in children. Rifampicin is widely used 
as part of anti-tuberculosis therapy and TMP/SMX is a commonly used prophylactic 
agent against Pneumocystis jiroveci in HIV-infected patients. Unfortunately, clindamycin 
resistance rates were noted to be high in both the KZN and national studies, as well as 
in a more recent report by Bamford et al. (2011), who reported 55-88% clindamycin 
resistance across the country. This limits the usefulness of clindamycin against MRSA 
infections in the South African setting until susceptibility results are known. All S. aureus 
isolates tested were susceptible to vancomycin, teicoplanin and fusidic acid (Shittu & 
Lin, 2006; Marais et al., 2009). Based on these antimicrobial susceptibility patterns, S. 
aureus appears to be a predominantly hospital-acquired pathogen in South Africa. CA-
MRSA isolates from other countries usually displayed increased susceptibility to non-
beta-lactam antibiotics (Bassetti et al., 2009).  
 
Management of SAB infections 
Antibiotic choice and duration of treatment of SAB infections varied according to the 
clinical diagnosis at the time of bacteraemia. In Kenya, children with SAB without a 
focus were less likely to receive correct empiric antibiotics than those with a focus 
(Ladhani et al., 2004). Similarly, only 36% of patients in Australia and 69% of patients in 
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the United Kingdom received the correct empiric antibiotics, with 65% having received 
less than two weeks of effective therapy (Suryati & Watson, 2002; Denniston & Riordan, 
2006). CA-MRSA infections were even less likely to have received the correct initial 
antibiotics – only 29% of children with CA-MRSA infections in Taiwan received 
successful empiric therapy (Chen et al., 2007). 
 
In accordance with international standards of care, bone and joint infections were 
treated for the longest period - approximately 46-50 days (Hill et al., 2001; Denniston & 
Riordan, 2006). Bacteraemia without a focus, however, was only treated for 6 days on 
average in New Zealand (Hill et al., 2001) and 7.5 days in the United Kingdom 
(Denniston & Riordan, 2006). This is far shorter than the traditional 14 days of therapy 
for uncomplicated SAB. In addition, the Infectious Diseases Society of America recently 
published guidelines recommending that MRSA bacteraemia be treated for at least 14 
days in the absence of any complicating factors (Liu et al., 2011).   
 
Outcomes  
SAB mortality rates differ between developed and developing countries. A population 
based study of SAB in children in Denmark over 30 years, showed that mortality rates 
dropped from 19.6% to 2.5% between 1971 and 2001 (Frederiksen et al., 2007). Case 
fatality rates between 0.7% and 3.2% were noted in New Zealand, Australia, England 
and the USA (Hill et al., 2001; Suryati & Watson, 2002; Denniston & Riordan, 2006; 
Burke et al., 2009). However, mortality was significantly higher in Kenya with a case 
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fatality rate of 24.7% (Ladhani et al., 2004). Children in the Kenyan study were at higher 
risk of death if there was no identified focus of SAB (46.7% mortality rate) compared to 
a 5.8% mortality rate in those with a focus of infection. Lack of appropriate empiric 
antibiotic therapy contributed to the higher risk of death in children without a focus of 
infection. Children with MRSA also had higher mortality rates - 7.3% in the United 
Kingdom, and 10% in the United States (Adedeji & Gray, 2005; Burke et al., 2009). 
Bacteraemia together with pulmonary infections were noted to contribute to mortality in 
infants and children over 10 years of age, while endocarditis was a significant risk factor 
for mortality in children less than 10 years (Frederiksen et al., 2007).  
 
AREAS FOR FUTURE RESEARCH 
This review has clearly demonstrated that S. aureus is a significant aetiological agent in 
paediatric bacteraemia in Africa, and the clinical epidemiology of this infection in 
children in South Africa warrants further investigation. Areas for future research should 
include the evaluation of the incidence of both community and hospital-acquired S. 
aureus bacteraemia in South African children. Reported rates of MRSA infection are 
high in combined adult and paediatric studies but there is a paucity of information on 
MRSA infection in children alone.  Knowledge of local epidemiology, including spectrum 
of the disease, clinical presentation and local risk factors for SAB would influence 
empiric disease management of both community and hospital-acquired bacteraemia. 
CA-MRSA has been reported in only two South African studies. Additional detailed 
studies are required to identify the magnitude of this problem in children. Investigations 
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that combine clinical and molecular typing of S. aureus are essential to clearly describe 
CA-MRSA. Mortality in children with SAB is reported to be high in Africa and much 
lower in the developed world. With a burgeoning HIV epidemic and a high incidence of 
malnutrition, it is imperative to undertake studies that elucidate the relationship between 
these conditions and S. aureus bacteraemia and their combined effects on mortality. 
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ABSTRACT 
Background: Staphylococcus aureus is an important pathogen in paediatric patients 
with bloodstream infections. The epidemiology of S. aureus bacteraemia (SAB), 
however, has not been well documented in children in South Africa.  
Methods: A retrospective study was conducted at a children’s hospital in Cape Town, 
South Africa, to investigate the epidemiology of SAB from 2007-2011. The incidence, 
clinical presentation, risk factors, management and outcomes of methicillin sensitive S. 
aureus (MSSA) and methicillin resistant S. aureus (MRSA) bacteraemia were 
compared. 
Results: Over the five year study period, 365 episodes of SAB were identified. The 
annual incidence of SAB was 3.28 cases per 1000 hospital admissions. MRSA was 
responsible for 26% of SAB and 72% of nosocomial infections. Only six possible cases 
of community-acquired MRSA infections were described. MSSA bacteraemia was more 
likely to present as pulmonary and bone or joint infections, while bacteraemia without a 
source was the most common presentation with MRSA.  Infants, children with 
malnutrition, and residents of long-term care facilities were at highest risk for MRSA 
bacteraemia. The overall case fatality rate for SAB was 8.8% over five years, with 
MRSA being the only significant risk factor for mortality.  
Conclusion: The incidence of SAB and MRSA bacteraemia in children has remained 
stable over the past five years. MRSA is a predominantly nosocomial pathogen in 
children with SAB in Cape Town, South Africa. 
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INTRODUCTION 
Staphylococcus aureus is a major human pathogen that causes a wide variety of 
infections ranging from skin and soft tissue infections to life-threatening invasive 
disease. This highly adaptive organism is a significant source of bacteraemia, 
responsible for both community-acquired and nosocomial infections.  In Africa, several 
studies have investigated the incidence of both community and hospital-acquired 
bloodstream infections in children presenting with signs of systemic infection. The 
overall incidence of S. aureus bacteraemia (SAB)  varies widely from 10% in Tanzania, 
to 12.5% in Kenya and 48.7% in Nigeria.1-3 The high incidence noted in Nigeria 
however, is most likely due to the disproportionate number of neonates included in that 
study. Few South African studies have characterized the contribution of S. aureus to 
bacteraemia in children.   In Cape Town, 11.6% of bacteraemia in hospitalized children 
were due to S. aureus, while SAB rates of 10.6%, 11% and 15.7% were reported in 
specific cohorts of HIV-infected children.4-7  
 
Methicillin resistant S. aureus (MRSA) is one of the commonest aetiologic agents of 
healthcare-associated and nosocomial infection amongst both adults and children 
worldwide, and the incidence of MRSA has been increasing over the last few years.8 
Specific risk factors for healthcare-associated infection include hospitalization or surgery 
within one year of infection, residence in a long-term care facility, presence of an 
invasive device at the time of admission, and history of MRSA infection or colonization.9 
In the only two paediatric studies in South Africa on S. aureus infections, 2% of isolates 
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were reported as MRSA at Red Cross War Memorial Children’s Hospital in 1974, while 
a second study, focusing on endocarditis in 36 children with SAB in Johannesburg, 
noted an MRSA rate of 31% in 1995.10,11 More recently, an antimicrobial susceptibility 
study on blood culture isolates from children and adults in South African public hospitals 
in 2010, identified 30-60% of S. aureus to be MRSA.12 Similarly, two international multi-
centre studies reported MRSA to be responsible for 33% and 39% of S. aureus 
infections in South Africa.13,14  
 
Since the late 1990’s, community-acquired MRSA (CA-MRSA) infections have been 
reported to be rapidly emerging.15 CA-MRSA is distinguished from healthcare-
associated MRSA (HA-MRSA) by the absence of any of the aforementioned risk factors. 
CA-MRSA isolates are often associated with a distinct antimicrobial sensitivity pattern 
and a different genetic background, alth ugh this distinction is now becoming more 
blurred as cases of HA-MRSA caused by strains with genotypes similar to that 
described in CA-MRSA isolates have been described.16   Reports of the prevalence of 
CA-MRSA vary widely across the world. Studies in the United States have reported CA-
MRSA to account for 40% of MRSA infections in New England compared to 74% in 
Texas.17,18 Notably, the majority of these infections (96-100%) were related to skin and 
soft tissue infections and not invasive disease. Bacteraemia due to CA-MRSA infections 
was reported to account for 4.7% of CA-MRSA in a Taiwanese study and 9.8% in the 
United Kingdom.19,20 In South Africa, a study conducted in Cape Town identified 10 
possible CA-MRSA amongst 100 MRSA isolates in both adults and children while an  
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adult study in Johannesburg reported 20% of MRSA bacteraemia to have originated 
from the community.21,22  
 
The aims of this study were to investigate the epidemiology of SAB at a single children’s 
hospital in South Africa over a five year period, and to describe the incidence, clinical 
presentation, microbiologic profiles, risk factors, management and outcomes of children 
with both methicillin-sensitive S. aureus (MSSA) and MRSA bacteraemia.  
 
MATERIALS AND METHODS 
Study population 
This study was undertaken at Red Cross War Memorial Children’s Hospital 
(RCWMCH), a tertiary level children’s hospital in Cape Town, South Africa, which 
serves as a major referral centre in the Western Cape province for children up to 13 
years. While the hospital does not provide routine postnatal care or have a dedicated 
neonatal intensive care facility, acutely ill neonates or those requiring paediatric surgery 
are managed at the hospital. 
 
Study design 
A retrospective analysis was conducted of all paediatric patients seen at RCWMCH with 
S. aureus bloodstream infections between January 2007 and December 2011. All 
patients from whom S. aureus had been isolated from blood culture specimens over the 
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five year period were identified using the National Health Laboratory Service (NHLS) 
database. Hospital clinical records were then retrospectively examined. Data were 
collected on demographics, clinical diagnosis, risk factors for infection, clinical and 
laboratory markers of infection, antibiotic susceptibility profiles, management of infection 
and clinical outcome.   
 
Definitions 
SAB was defined as the isolation of S. aureus from a blood culture specimen. Isolates 
were identified and tested for antimicrobial susceptibility at Groote Schuur Hospital 
NHLS microbiology laboratory, according to Clinical and Laboratory Standards Institute 
guidelines.23 All S. aureus organisms cultured from blood specimens were considered to 
be clinically significant. However, multiple isolates of the same organism from the same 
patients were excluded from analysis if they were clinically deemed to be related to the 
incident infection. The isolation of S. aureus from a blood culture drawn more than 48 
hours after admission to hospital, or drawn at readmission within 48 hours of discharge, 
was considered to be a nosocomial infection. Based on the definitions utilized by the 
Centers for Disease Control and Prevention, healthcare-associated infections were 
defined as those that occurred within 48 hours of admission to hospital, with at least one 
of the following healthcare-associated risk factors: hospitalization or surgery within one 
year of onset of infection, presence of an invasive device at the time of admission, 
resident of a long-term care facility, and history of MRSA colonization or infection. 
Community-acquired MRSA infections were those identified within 48 hours of hospital 
admission, but with none of the aforementioned healthcare-associated risk factors.9 
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Clinical diagnoses during the SAB episode were classified according to the assessment 
of the attending physician in the patient records. HIV infection was determined by HIV 
PCR testing in children younger than 18 months, and by HIV ELISA testing in children 
over 18 months. HIV exposure was identified by history of maternal HIV infection, or a 
positive HIV antibody test in infants less than 18 months who tested HIV PCR negative. 
Leucocytosis was regarded as a white cell count above the normal range for age 
according to the NHLS reference standards. Malnutrition was defined according to 
WHO growth standards as weight-for-height or height-for-age z-score -2 SD below the 
mean WHO reference values. Severe malnutrition was defined as weight-for-height or 
height-for-age z score below -3SD of the mean, or by the presence of nutritional 
oedema.24 
 
Statistical analysis 
Weight-for-age z-scores (WAZ), height-for-age z-scores (HAZ) and weight-for-height z-
scores (WHZ) were calculated using Epi-Info, version 3.5.3 (2011). Data were analysed 
using Stata Statistical Software version 11.1 (StataCorp, College Station, Texas). Non-
parametric variables were evaluated with Wilcoxon rank-sum tests and Kruskal-Wallis 
tests, and categorical data with chi-square tests. Odds ratios, together with 95% 
confidence intervals, were utilized to describe measures of effect. For all analyses, p 
<0.05 was considered statistically significant. Logistic regression was performed to 
assess risk factors for MRSA infection and risk factors for mortality. Variables with p 
<0.1 on univariate analysis were selected for stepwise forward multivariate analysis. 
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Ethical considerations 
The study was conducted in accordance with the Declaration of Helsinki and was 
approved by the Departmental Research Committee of the Department of Child and 
Adolescent Health, and the Research Ethics Committee, Faculty of Health Sciences, 
University of Cape Town (HREC REF:029/2011).  
 
RESULTS 
Between January 2007 and December 2011, 365 episodes of S. aureus bacteraemia 
(SAB) were identified, 270 with MSSA and 95 with MRSA. Seventeen patients had two 
distinct episodes of SAB based on clinical presentation. S. aureus was isolated on 
subsequent culture specimens, including blood, bone, tissue, pus, pleural, pericardial, 
peritoneal and synovial fluids in 143/365 episodes (39%). Basic demographic (age, 
gender), laboratory and microbiological data were accessible for all SAB episodes. 
Unfortunately, due to the retrospective design of the study, clinical and outcome data 
were not available for all cases.  
 
Incidence of infection 
The annual incidence of SAB was 3.28 cases/1000 hospital admissions per year with a 
mean frequency of 2.43 MSSA cases and 0.85 MRSA cases per 1000 hospital 
admissions per year. Overall, MRSA was responsible for 26% of bacteraemia episodes 
due to S. aureus. There was no significant change in the frequency of SAB over the 
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study period (p=0.379) (Figure 1). While rates of MRSA infection remained fairly 
constant from 2007-2011, the incidence of nosocomial SAB rose steadily from 2007 and 
peaked in 2010 (Figure 2). 
 
Characteristics of study population 
Demographic characteristics and basic infective markers of the cohort are outlined in 
Table 1. The median age of staphylococcal bacteraemia was 11 months. Neonates 
accounted for 36/365 (9.9%) of episodes while infants represented 189/365 (51.8%) of 
SAB. Children with MRSA infection were significantly younger (p=0.026), and more 
frequently underweight (p=0.0000) and stunted (p=0.0000). In those children whose HIV 
exposure and testing status was known, 51 (19.8%) were HIV-infected and 48 (19.4%) 
were HIV-exposed but uninfected (Table 1). Notably 107 (29%) children had an 
unknown HIV status. HIV infection, but not HIV exposure, was significantly associated 
with MRSA bacteraemia (p=0.001). Analysis of infective markers, including white cell 
count (WCC), neutrophil count, band count and C-reactive protein (CRP), revealed no 
differences between MSSA and MRSA bacteraemia (Table 1).  
 
Spectrum of S. aureus infections 
The origin of SAB, was identifiable in 357/365 episodes: 33% (118/357) were 
nosocomial, 16% (56/357) healthcare-associated and 51% (183/357) community-
acquired. MRSA was responsible for 21% of healthcare-associated and 72% of 
nosocomial infections. Six MRSA infections were classified as community-acquired with 
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no identifiable healthcare-associated risk factors (one in 2007, one in 2009, three in 
2010 and one in 2011). Primary diagnoses for these cases were bacteraemia without 
identified source (4), gastroenteritis (1) and superficial skin sepsis (1).  
 
Data on clinical diagnosis, available for 337 episodes of SAB (Table 2), showed that  
the most common clinical diagnosis was SAB without an identifiable source (33%), 
followed by SAB with pneumonia ± empyema (22%), SAB with skin and soft tissue 
infections (17%) and SAB with bone or joint infections (12%). Bloodstream infections 
without a source were more likely to be MRSA infections, while pulmonary, bone and 
joint infections were more likely to be due to MSSA. The only two bone or joint 
infections caused by MRSA were nosocomial in origin. Central venous catheter-related 
line sepsis was equally likely to be attributable to MSSA or MRSA, although all were 
nosocomial in origin (Table 2). 
 
Risk factors for MRSA infection 
Univariate analysis showed that prior hospitalization within one year, presence of an 
indwelling medical device, previous MRSA infection, being a resident of a long-term 
care facility, HIV infection,  malnutrition, congenital cardiac disease, concurrent 
tuberculosis, duration of incident hospitalization and infancy (under 12 months), were 
significant risk factors for MRSA infection (Table 3).  On multivariate analysis, infancy, 
resident of a long-term care facility, malnutrition, and longer duration of incident 
hospitalization remained significant risk factors.   
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Microbiologic profile 
Results of antimicrobial susceptibility testing, available for all 365 isolates (Table 4), 
suggested that most MSSA isolates were susceptible to the majority of antibiotics 
tested. Only 6% of MSSA were susceptible to penicillin. Most MRSA isolates displayed 
multi-drug resistance. All MRSA were sensitive to vancomycin (minimal inhibitory 
concentration (MIC) ≤ 2µg/ml); three isolates were reported to have a vancomycin MIC 
equal to 2µg/ml. All three cases were treated successfully – catheter-related sepsis in a 
preterm infant with vancomycin alone, pneumonia in an HIV-infected child with 
vancomycin and clindamycin used sequentially, and bacteraemia without source in a 
child with short bowel syndrome with a combination of vancomycin and trimethoprim-
sulfamethoxazole (TMP/SMX). Organisms isolated from HIV-infected patients were 
more likely to be resistant to TMP/SMX (63% vs. 21%) (p=0.000), gentamicin (55% vs. 
24%) (p=0.000) and rifampicin (51% vs. 16%) (p=0.000). Of the 32 HIV-infected 
patients with TMP/SMX resistant isolates, 22 (69%) were on TMP/SMX prophylaxis at 
the time of SAB. Antimicrobial resistance patterns were similar in children who were 
HIV-exposed but uninfected, compared to children who were not exposed to HIV.  
 
In 84/365 (23%) of SAB episodes, a concomitant organism was isolated on blood 
culture. Once typical skin contaminants (coagulase negative staphylococci, bacillus spp. 
and corynebacterium spp.) were excluded, 24/365 cultures (7%) had a clinically 
significant second organism (polymicrobial bacteraemia) – gram negative bacilli (10), 
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Enterococcus faecalis or faecium (9) and Streptococcus pyogenes or agalactiae. (5). 
Infants (11%), children with malnutrition (10.5%) and those with MRSA bacteraemia 
(12.6%) were more likely to have a significant concomitant organism on culture. No 
association was found between polymicrobial bacteraemia and HIV infection or HIV 
exposure on chi-square analysis.  
 
Antibiotic management 
Data on appropriate antibiotic therapy, which was regarded as the administration of 
antibiotics to which the organism was sensitive, were available for 322 episodes. At the 
time the culture was drawn, 31/322 (9.6%) were already on antibiotics to which the 
organism was sensitive and likely to respond clinically. The majority of these episodes 
(29/31; 94%) were caused by MSSA and 25/31 (81%) were community-acquired 
infections. Twelve of these patients received a dose of intramuscular ceftriaxone for 
suspicion of severe bacterial infection at a primary care clinic prior to transfer to 
RCWMCH, in keeping with South African Integrated Management of Childhood Illness 
guidelines.25 The median time on therapy before the blood culture was drawn was 6 
hours (IQR 1.5-22.7 hours).  
 
Excluding those who were already on antibiotics at the time of culture, appropriate 
antibiotic therapy was instituted in 267/322 (82.9%) episodes of SAB. Time to 
appropriate therapy was calculated if the precise time of blood draw and time of 
antibiotic administration were documented. This information was available in 141 
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episodes. Appropriate therapy was initiated within a median time of 2.5 hours (IQR 0.7-
8.5) in MSSA and 46 hours (IQR 4.7-55.3) in MRSA infections (p=0.0000). The median 
time to initiation of therapy was 2.5 hours for community-acquired infections, 5.8 hours 
for healthcare-associated infections, and 10.6 hours for nosocomial infections 
(p=0.0019). There was no significant difference in time to therapy when comparing 
episodes with an identified source of bacteraemia and those without.  
 
The remaining 24/322 episodes (7.5%) did not receive appropriate antimicrobials. In 
18/24 cases, the S. aureus isolated was clinically regarded to be a contaminant. The 
remaining six untreated patients died; in 5 cases, death occurred before blood culture 
results became available while in one case, the MRSA isolated was considered to be a 
contaminant. Two deaths occurred upon arrival at RCWMCH with pulmonary infections 
caused by MSSA noted on autopsy. The remaining four deaths were related to MRSA 
bacteraemia without a source; three of these were also malnourished.  
 
Total treatment duration, which was known for 261 episodes, varied according to the 
clinical diagnosis. The overall treatment duration was 14 days (IQR 7-29 days). 
Endocarditis, pulmonary and bone or joint infections were treated for a median of 44 
days (IQR 39-51 days), 13 days (IQR 7-23 days) and 40 days (IQR 32-79 days) 
respectively. Central venous catheter-related infections were treated for 16 days (IQR 
13-28 days); 8/11 episodes required line removal due to recurrent isolation of S. aureus. 
SAB without a source was treated for a median of 9 days (IQR 6-14 days).  
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Outcomes 
According to clinical records, 32 deaths were attributed to SAB, resulting in a case 
fatality rate of 8.8% over the five year period. Median time to death was 3.5 days (IQR 
1.5-6.5 days). SAB without a source accounted for 59% of deaths, while pulmonary 
infection was responsible for an additional 25% of mortality. There were no deaths 
attributed to central venous catheter-related infection. MRSA accounted for 53% of 
deaths. Factors contributing to mortality on univariate analysis included MRSA infection 
(OR 3.71; CI 1.77-7.66), HIV infection (OR 2.91; CI 1.23-6.87) and malnutrition (OR 
2.45; CI 1.17-5.12) (Table 5).  An identifiable source of SAB infection (OR 0.3; CI 0.14-
0.62), and initiating appropriate antibiotic therapy within eight hours of blood culture, 
had a protective effect (OR 0.32; CI 0.13-0.77). Age, polymicrobial bacteraemia and the 
occurrence of multiple positive cultures for S. aureus, were not associated with 
mortality. On multivariate analysis, only MRSA remained a significant risk factor for 
mortality (OR 3.76; CI 1.12-12.67).  
 
DISCUSSION 
This report is the first comprehensive study of the epidemiology of S. aureus 
bacteraemia in children in South Africa. International trends show increasing rates of 
MRSA and stable rates of MSSA bacteraemia in children over the last 20 years. In 
England and Wales, a large multicenter study, reported an increase in the proportion of 
MRSA bacteraemia from 0.9% in 1990 to 13% in 2000.26 In the United States, 
Wisplinghoff et al. (2003) reported MRSA bacteraemia to have increased from 10% in 
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1995 to 29% in 2001 in 49 paediatric hospitals throughout the country, while Burke et al. 
(2009) reported a similar increase of 9% in 2001 to 24% in 2006 in California.27,28 No 
published data are available for Africa on the trends of SAB in children. In this study, the 
incidence of SAB and MRSA bacteraemia remained fairly constant over the period 2007 
to 2011. MRSA rates in children in South Africa have shown a distinct upward trend 
from 2% in 1974, 18% in 1992, to 26% in this study.4,10  However, the MRSA rate 
reported in the present study, is lower than the 30-60% among adults and children in 
public sector hospitals in South Africa in 2010.12  
 
Nosocomial and healthcare-associated infection accounted for approximately half of all 
cases of SAB. Rates of nosocomial infection increased between 2009 and 2010 
possibly due to a concurrent measles epidemic in 2009-2010, and then declined in 
2011. There was a marked decline in the number of healthcare-associated infections 
from 2008 to 2011. There was no clear reason for this decline. Changes in S. aureus 
colonization rates within the hospital may be responsible for this observation, but further 
investigation is required. In this study, MRSA was a predominantly nosocomial or 
healthcare-associated pathogen. The proportion of CA-MRSA isolates identified (6.3%), 
is lower than those of other South African reports.21,22 This study, however, focused on 
bloodstream infections, while most cases of CA-MRSA have been reported with skin 
and soft tissue infections. Due to the retrospective study design, molecular typing was 
not available for the CA-MRSA isolates. 
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 As reported in other studies, infants are at greatest risk of SAB, especially with regards 
to MRSA bacteraemia.26,29 In our cohort, they were also more likely to present with a 
concomitant organism on blood culture. This susceptibility to systemic bacterial illness 
may be attributed to the relative immaturity of immune responses in infants. HIV-
infected children also have an increased risk of bacteraemia.30,31 A sizable proportion of 
our cohort (20%) was HIV-infected, of which 49% had MRSA bacteraemia. Other South 
African studies also demonstrated high rates of MRSA in HIV-infected children ranging 
from 77-100%.5-7 This may be due to the fact that HIV-infected children are more likely 
to be hospitalized than other children. Several common infective markers were also 
analyzed but were unable to distinguish MSSA from MRSA bacteraemia (Table 1). 
 
Bacteraemia without a source was the most common clinical diagnosis. All community-
acquired bone or joint infections were MSSA in origin, which supports the empiric 
antibiotic choice of cloxacillin for osteomyelitis and septic arthritis at RCWMCH. 
Endocarditis was only diagnosed in 2.4% of episodes of SAB.  Although children in this 
study were not screened with echocardiography, other studies have also shown that 
endocarditis with SAB is an uncommon event in children compared to adults.28,29,32   
  
As most episodes of MRSA bacteraemia were nosocomial or healthcare-associated 
infections, the antimicrobial sensitivity pattern reflected predominantly multi-drug 
resistant MRSA isolates, which is in agreement with antimicrobial susceptibility studies 
on both adults and children in South Africa.33,34  All isolates were susceptible to 
vancomycin, which remains the drug of choice for managing MRSA infections in 
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children.  Notably, HIV-infected children were observed to be infected with S. aureus 
isolates that were more likely to be resistant to TMP/SMX, gentamicin and rifampicin. 
This may be due to the use of TMP/SMX in most HIV-infected children for prophylaxis 
against Pneumocystis jiroveci infection, while gentamicin is a common first line antibiotic 
agent for all children presenting to hospital with sepsis. Many children with HIV are 
treated with rifampicin for TB during their clinical course, which may account for the high 
rates of rifampicin resistance in this cohort.     
 
The median time to appropriate therapy in this study was significantly delayed for MRSA 
infections, but this did not impact on mortality. Identifying children with risk factors for 
MRSA infection allows better guidance for empiric antibiotic therapy for nosocomial and 
healthcare-associated infections. In this setting, infants, malnourished children, and 
residents at long-term care facilities should be treated with vancomycin as part of their 
empiric antibiotic coverage for nosocomial infection if S. aureus is considered likely, 
until results of antimicrobial sensitivities are available.  The recent clinical practice 
guidelines, published by the Infectious Diseases Society for America for the treatment of 
MRSA infections in adults and children, advise treating uncomplicated SAB with at least 
14 days of appropriate antibiotic therapy.35 The treatment duration for this category of 
patient was observed to be shorter in our cohort. In our study it was not possible to 
determine if shorter courses of treatment for SAB without a source were as effective as 
two weeks of therapy.      
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The retrospective nature of the study imposed some limitations. The number of SAB 
episodes reported may be an underestimate of the true incidence of disease due to 
non-standardized indications for blood culture, variability in blood culture volumes 
collected in paediatric practice, and the initiation of antibiotics in some cases prior to 
blood culture collection. The absence of molecular typing of MRSA isolates limited the 
complete evaluation of identified CA-MRSA organisms. Moreover, our study had a high 
incidence of concomitant organisms which were not excluded from analysis, as their 
presence on blood culture did not preclude the presence of a significant infection with S. 
aureus. 
  
This study presents important clinical and epidemiological information not previously 
available on S. aureus bacteraemia in children in South Africa. Although rates of SAB 
and MRSA bacteraemia were stable in our population, MRSA was a significant source 
of nosocomial infection and was a major risk factor for mortality in children with SAB. 
Prospective studies that combine clinical and molecular epidemiology of S. aureus 
infections in children are warranted. 
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Figure 1: Incidence of S. aureus bacteraemia (SAB), methicillin-sensitive S. aureus 
(MSSA) and methicillin-resistant S. aureus (MRSA) bacteraemia per 1000 hospital 
admissions  
 
  
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
2007 2008 2009 2010 2011
In
ci
d
e
n
ce
 o
f 
S
A
B
 p
e
r 
1
0
0
0
 h
o
sp
it
a
l 
a
d
m
is
si
o
n
s
Year
Overall SAB 
MSSA 
MRSA 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
68 
 
 
 
 
 
 
 
Figure 2: Incidence of community-acquired, healthcare-associated & nosocomial S. 
aureus bacteraemia per 1000 hospital admissions  
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Table 1: Characteristics of patients at S. aureus bacteraemia diagnosis 
 All patients MSSA MRSA p 
Median age in 
months (IQR) 
(n=365) 
11.3 (3.8-42.3) 
(n=270) 
14.0 (3.7-51.1) 
(n=95) 
7.1 (3.8-19.6) 
 
0.026 
Male: Female 193:172 151:119 42:53 0.049 
Median weight-
for-age z-score 
(IQR) 
 
(n=331) 
-1.53 
(-3.09;-0.36) 
 
(n=249) 
-1.24 
(-2.35;-0.17) 
 
(n=82) 
-3.00 
(-4.35;-1.38) 
 
0.0000 
Underweight for 
age (%) 
(n=331) 
131 (39.6%) 
(n=249) 
79 (31.7%) 
(n=82) 
52 (63.4%) 0.0000 
Median height-
for-age z-score 
(IQR) 
 
(n=167) 
-1.69 
(-3.11;-0.6) 
 
(n=103) 
-1.39 
(-2.23;-0.5) 
 
(n=64) 
-2.65 
(-3.82;-1.01) 
 
0.0002 
Stunted (%) (n=167) 76 (45.5%) 
(n=103) 
35 (34%) 
(n=64) 
41 (64.1%) 0.0000 
Median weight-
for-height 
z-score (IQR) 
 
(n=149) 
-1.53 
(-3.12;0.21) 
 
(n=88) 
-1.40 
(-3.13;0.4) 
 
(n=61) 
-1.94 
(-3.08;-0.01) 
 
ns 
HIV infection 
(%) 
(n=258) 
51 (19.8%) 
(n=179) 
26 (14.5%) 
(n=79) 
25 (31.6%) 
 
0.001 
HIV exposed 
but uninfected 
(%) 
 
(n=248) 
48 (19.4%) 
(n=180) 
39 (21.7%) 
(n=68) 
9 (13.2%) ns 
Median white 
cell count x 
109/L (IQR) 
 
(n=354) 
14.2 (9.3-20.8) 
(n=262) 
14.3 (8.9-20.4) 
(n=92) 
13.8 (9.7-21.6) ns 
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(IQR = Interquartile range; CRP = C-reactive protein; ns= Not significant) 
 
 
 
 
 
 
 
 
  
Leucocytosis 
(%) 
(n=354) 
157 (44.4%) 
(n=262) 
123 (47%) 
(n=92) 
34 (37%) ns 
Median 
neutrophil 
count  x 109/L 
(IQR) 
 
(n=277) 
5.6 (2.9-10.6) 
(n=204) 
5.5 (2.9-10.4) 
(n=73) 
5.7 (2.5-11.2) ns 
Median band 
count  x 109/L 
(IQR) 
 
(n=268) 
1.7 (0.48-3.6) 
(n=198) 
1.7 (0.47-3.27) 
(n=70) 
1.9 (0.49-4.3) ns 
Median CRP 
mg/L (IQR) 
(n=193) 
53.6 (15.2-175.5) 
(n=146) 
54.5 (14.4-176.7) 
(n=47) 
48.8 (16.1-134) ns 
Median 
temperature at 
time of blood 
culture 0C (IQR)  
(n=321) 
380C 
(37.0-38.80C) 
(n=246) 
38.00C 
(36.9-38.80C) 
(n=75) 
38.10C 
(37.3-38.90C) 
ns 
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Table 2: Clinical diagnosis at the time of S. aureus bacteraemia 
Clinical 
diagnosis at 
the time of 
culture 
All MRSA MSSA OR (95%CI) p 
Bloodstream 
infection with 
no source 
110 (32.6%) 41 (50%) 69 (27.1%) 2.70 (1.56-4.65) 0.0001 
Pneumonia & 
Empyema 73 (21.7%) 10 (12.2%) 63 (24.7%) 0.42 (0.18-0.89) 0.0167 
Skin and soft 
tissue 
infections 
58 (17.2%) 18 (22%) 40 (15.7%) 1.51 (0.76-2.91) ns 
Bone and joint 
infections 39 (11.6%) 2 (2.4%) 37 (14.5%) 0.15 (0.02-0.60) 0.003 
Gastroenteritis 20 (5.9%) 2 (2.4%) 18 (7.1%) 0.33 (0.04-1.43) ns 
Staph scalded 
skin syndrome 11 (3.3%) 0 11 (4.3%) - - 
Central venous 
catheter-
related 
infection 
11 (3.3%) 6 (7.3%) 5 (2%) 3.95 (0.97-16.74) ns 
Endocarditis 8 (2.4%) 2 (2.4%) 6 (2.4%) 1.04 (0.10-5.95) ns 
Meningitis 2 (0.6%) 1 (1.2%) 1 (0.4%) 3.14 (0.04-247.1) ns 
Pericardial 
effusion 2 (0.6%) 0 2 (0.8%) - - 
Other 3 (0.9%) 0 3 (1.2%) - - 
TOTAL  337 (100%) 82 (100%) 255 (100%) - - 
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Table 3: Risk factors for methicillin-resistant S. aureus (MRSA) bacteraemia 
Risk factors for MRSA 
infection 
Univariate Analysis Multivariate analysis 
Odds Ratio (95% CI) Odds Ratio (95% CI) 
Hospitalization within 1 year 2.89 (1.79-4.68)* 0.92 (0.41-2.06) 
Surgery within 1 year 1.65 (0.94-2.91) 2.28 (0.73-7.10) 
Indwelling device 2.02 (1.09-3.74)* 0.87 (0.25-3.10) 
Prior MRSA infection 16.8 (4.7-60.11)* 6.54 (0.91-46.98) 
Resident of a care facility 12.68 (4.04-39.76)* 47.94 (7.0-326.8)* 
Gender 1.6 (0.99-2.56) 1.48 (0.69-3.14) 
Age (infant vs. children >1 
year) 2.05 (1.26-3.34)* 2.39 (1.07-5.38)* 
Duration of incident 
hospitalization 1.06 (1.04-1.08)* 1.06 (1.03-1.09)* 
HIV-infected 2.72 (1.45-5.12)* 1.84 (0.72-4.69) 
HIV-exposed but uninfected 0.55 (0.25-1.21) - 
 
Malnutrition 4.45 (2.65-7.5)* 3.12 (1.40-6.96)* 
Congenital cardiac disease 2.65 (1.30-5.38)* 0.37 (0.09-1.61) 
Concurrent tuberculosis 6.76 (2.24-20.39)* 1.40 (0.23-8.44) 
Chronic lung disease 1.53 (0.28-8.51) - 
 
Chronic renal disease 0.75 (0.21-2.74) - 
 
Malignancy 2.74 (0.89-8.38) - 
 
Burns 1.23 (0.37-4.01) - 
 
Long-term 
steroid/immunosuppressant  
use 
1.54 (0.38-6.29) - 
 
(*p<0.05) 
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Table 4: Antimicrobial susceptibility results of methicillin-sensitive S. aureus (MSSA) 
and methicillin-resistant S. aureus (MRSA) isolates 
Antibiotic 
Number (%) of sensitive isolates 
MSSA MRSA  
Penicillin 15 (5.6) 0 (0) 
Cloxacillin 270 (100) 0 (0) 
Clindamycin 254 (94.4) 17 (17.9) 
Erythromycin 251(93.3) 14 (14.7) 
TMP/SMX 240 (89.2) 37 (38.9) 
Vancomycin 269 (100) 95 (100) 
Ciprofloxacin 263 (98.5) 44 (46.8) 
Gentamicin 238 (88.8) 20 (21.3) 
Rifampicin 261 (97.4) 37 (39.4) 
Fusidic acid 266 (100) 91 (95.8) 
Moxifloxacin 28 (100) 15 (78.9) 
Linezolid 128 (100) 50 (100) 
Teicoplanin 36 (100) 19 (100) 
Tigecycline 28 (100) 19 (100) 
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Table 5: Risk factors for mortality with S. aureus bacteraemia  
Risk factors for 
Death 
Univariate Analysis Multivariate analysis 
Odds Ratio (95% CI) Odds Ratio (95% CI) 
MRSA bacteraemia 3.71 (1.77-7.76)* 3.76 (1.12-12.67)* 
HIV infection 2.91 (1.23-6.87)* 3.12 (0.99-9.78) 
HIV exposed but 
uninfected 0.31 (0.07-1.40) - 
 
Malnutrition 2.45 (1.17-5.12)* 1.7 (0.49-5.81) 
Age  0.84 (0.40-1.74) 
  
Gender 1.98 (0.94-4.19) 1.6 (0.52-4.92) 
Appropriate antibiotics 
within 8 hours of blood 
culture 
0.32 (0.13-0.77)* 0.54 (0.17-1.67) 
Identified source of 
infection 0.3 (0.14-0.62)* 0.39 (0.12-1.22) 
Multiple positive 
cultures for S. aureus 1.22 (0.59-2.55) - 
 
Polymicrobial 
bacteraemia  2.28 (0.81-6.44) - 
 
 
*(p<0.05)  
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DATA CAPTURE SHEET: EPIDEMIOLOGY OF S. AUREUS 
Study number   Folder number   
  
Date of birth   Gender Male  /  Female 
  
Date of admission 
 
Date of discharge   
  
Weight (kg)   Height (cm)   
  
Ward where Cx drawn   Date of positive S. aureus Cx   
Positive S. aureus culture MSSA    /    MRSA Time Cx was drawn   
Culture specimen   
Dates of subsequent positive S. aureus cultures   
Positive S. aureus cultures from other sites   
Concomitant organisms on blood culture   
  
Primary Clinical Diagnosis at time of culture 
Bacteraemia no source   Osteomyelitis   
Pneumonia   Septic arthritis   
Empyema   Gastroenteritis   
Endocarditis   Skin & soft tissue    
Meningitis   Other (specify)   
  
Additional clinical diagnoses 
1) 3) 
2) 4) 
  
Infective markers at time positive culture drawn (within 24 hours) 
WCC    Neutrophil count   
CRP   Band count   
ESR   Procalcitonin   
Temp at time of Cx   Date of peak temp   
Fever (>38˚C) duration from 
initiation of appropriate 
antibiotics  
< 12 hours 24-48 hours 72-96 hours 
12-24 hours 48-72 hours >96 hrs :  
  
Risk factors: 
Hospitalization within 1 
year of positive culture 
Date: Date: Date: 
Dx: Dx: Dx: 
Surgery within 1 year  Date: Surgical Procedure   
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Indwelling device    H/O MRSA infection   
Resident of care facility   Other   
  
HIV infection Y    /  N    /   Not tested HIV exposed Y    /  N    /   Not tested 
Stage of HIV infection 1    /    2    /    3     /   4 Most recent CD4 count (%)   
Treatment with ART Yes   /   No Date of CD4 count    
Date ART initiated   Defaulted ART Yes  /  No 
Bactrim prophylaxis Yes   /   No Date of Default   
  
1˚ immune deficiency   Chronic lung disease   
Malnutrition   Cystic fibrosis   
Renal disease   Malignancy   
Diabetes   Immunosuppression   
Cong. cardiac disease   Burns   
Other   Concurrent tuberculosis   
Antibiotics at the time that culture was drawn 
Antibiotic   Antibiotic   
Route of admin   Route of admin   
Date started    Date started   
Date stopped   Date stopped   
  
Empiric antibiotics prescribed after blood culture drawn: 
Antibiotic   Antibiotic   
Route of admin   Route of admin   
Date & time started   Date & time started   
Date stopped   Date stopped   
  
Antibiotic   Antibiotic   
Route of admin   Route of admin   
Date & time started   Date & time started   
Date stopped   Date stopped   
  
Subsequent antibiotics prescribed: 
Antibiotic    Antibiotic   
Route of admin   Route of admin   
Date started   Date started   
Date stopped   Date stopped   
  
Antibiotic    Antibiotic   
Route of admin   Route of admin   
Date started   Date started   
Date stopped   Date stopped   
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Antibiotic Sensitivities: Date of Cx: Date of Cx: Date of Cx: 
Penicillin S  /  I  /  R S  /  I  /  R S  /  I  /  R 
Cloxacillin S  /  I  /  R S  /  I  /  R S  /  I  /  R 
Clindamycin S  /  I  /  R S  /  I  /  R S  /  I  /  R 
Erythromycin S  /  I  /  R S  /  I  /  R S  /  I  /  R 
Vancomycin S  /  I  /  R S  /  I  /  R S  /  I  /  R 
TMP/SMX S  /  I  /  R S  /  I  /  R S  /  I  /  R 
Ciprofloxacin S  /  I  /  R S  /  I  /  R S  /  I  /  R 
Moxifloxacin S  /  I  /  R S  /  I  /  R S  /  I  /  R 
Gentamicin S  /  I  /  R S  /  I  /  R S  /  I  /  R 
Rifampicin S  /  I  /  R S  /  I  /  R S  /  I  /  R 
Fusidic Acid S  /  I  /  R S  /  I  /  R S  /  I  /  R 
Linezolid S  /  I  /  R S  /  I  /  R S  /  I  /  R 
Teicoplanin S  /  I  /  R S  /  I  /  R S  /  I  /  R 
Tigecycline S  /  I  /  R S  /  I  /  R S  /  I  /  R 
Vancomycin MIC       
Vancomycin level/s 
(dates)       
  
Complications of infection: 
Surgical procedure + date   
ICU admission   High care admission   
Septic shock Fluid boluses / Inotropes Renal impairment  ↑Urea  / ↑Creat   / Dialysis 
Respiratory failure CPAP / IPPV Hepatic dysfunction ↑ Bili / ↑ ALT or AST / ↑INR 
Other   
Death (date & cause)   
  
SUSPECTED 
CONTAMINANT Yes  /  No Transfer to another hospital   
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electronically signing this form, go to http://links.lww.com/ZUAT/A106.  
Compliance with NIH and Other Research Funding Agency Accessibility 
Requirements 
A number of research funding agencies now require or request authors to submit 
the post-print (the article after peer review and acceptance but not the final 
published article) to a repository that is accessible online by all without charge. As a 
service to our authors, LWW will identify to the National Library of Medicine (NLM) 
articles that require deposit and will transmit the post-print of an article based on 
research funded in whole or in part by the National Institutes of Health, Wellcome 
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Trust, Howard Hughes Medical Institute, or other funding agencies to PubMed 
Central. The revised Copyright Transfer Agreement provides the mechanism. 
Permissions: Authors must submit written permission from the copyright owner 
(usually the publisher) to use direct quotations, tables, or illustrations that have 
appeared in copyrighted form elsewhere, along with complete details about the 
source. Any permissions fees that might be required by the copyright owner are the 
responsibility of the authors requesting use of the borrowed material, not the 
responsibility of Lippincott Williams & Wilkins.  
Preparation of Manuscript  
Manuscripts that do not adhere to the following instructions are returned to the 
corresponding author for technical revision before undergoing peer review. Also, to 
streamline the review process, on reviewing newly submitted manuscripts, we will 
identify those that do not meet the mission of the journal, provide no new 
information or insights into management of infectious diseases or are of more local 
importance and better suited for a regional journal and return them immediately to 
the authors to allow them to submit their work elsewhere in a timely fashion.  
New Article Types  
Research Reports This section comprises manuscripts on all aspects of the 
molecular pathogenesis and immunologic mechanisms of bacterial, viral, fungal and 
other infections in infants, children and adolescents. The emphasis will be on 
manuscripts that present data that are clinically applicable and provide a more 
thorough understanding of the pathophysiologic basis of infections in children and 
that could impact eventual treatment and prevention. The manuscripts can be 
formatted as original studies or brief reports and will be peer reviewed.  
HIV Reports The section comprises of high-quality, high-impact original articles 
and brief reports of epidemiologic, clinical, translational and implementation science 
studies pertaining to the prevention, treatment and outcomes of HIV infection in 
infants, children, and adolescents. 
 
Vaccine Reports Articles that present data from Vaccine Phase II-IV studies will 
appear in this section. These manuscripts receive the same peer review as articles 
submitted as Original Studies. The universal open access fee for all accepted 
manuscripts in this category is: $1500.00 US, plus an additional per-page fee with 
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2 options: 1) $50 per page for print and online publication; or 2) $25 per page for 
online only publication. All articles in this series will be available online by free 
access. For manuscripts in this category, authors should refer to the “Guidelines for 
collection, analysis and presentation of vaccine safety data in pre- and post-
licensure clinical studies” published in Vaccine (2009, vol. 27; pp 2282-8) and use 
case definitions as developed by The Brighton Collaboration 
(www.brightoncollaboration.org) whenever possible.  
 
Manuscript Submission 
 
Online manuscript submission: All manuscripts must be submitted on-line 
through the new web site at http://pidj.edmgr.com/. First-time users: Please click 
the Register button from the menu above and enter the requested information. On 
successful registration, you will be sent an E-mail indicating your user name and 
password. Print a copy of this information for future reference. Note: If you have 
received an E-mail from us with an assigned user ID and password, or if you are a 
repeat user, do not register again. Just log in. Once you have an assigned ID and 
password, you do not have to re-register, even if your status changes (that is, 
author, reviewer, or editor). If you experience any problems, please contact Amy 
Newman, Journal Manager, at PIDJournal@yahoo.com, Ph 830-865-
1249            830-865-1249      , Fax 214-710-2175.  
Authors: Please click the log-in- button from the menu at the top of the page and 
on the next screen log into the system as an Author. Submit your manuscript 
according to the author instructions. You will be able to track the progress of your 
manuscript through the system. If you experience any problems, please contact 
Amy Newman, Journal Manager, at PIDJournal@yahoo.com, Ph 830-865-
1249            830-865-1249      , Fax 214-710-2175. Requests for help and other 
questions will be addressed in the order received. To submit a completed 
manuscript, the following documents are required: Cover Letter, Title Page, 
Abstract, and Manuscript. Tables and figures are optional. Each portion of the 
manuscript must be submitted as separate documents (i.e. cover letter, title page, 
abstract, manuscript, tables and figures all saved as separate files). The text 
documents, cover letter, title page, abstract and manuscript are to be uploaded as 
Microsoft Word documents. Tables are to be created in Microsoft Word also. Excel 
tables will not load properly. All figures should be TIFF, EPS or PowerPoint files.  
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General format: Submit manuscripts in English. Double space all copy, including 
legends, footnotes, tables, and references. Use a common font such as Arial or 
Times Roman in size 12. Enumerate all pages of the manuscript, beginning with the 
Title Page as page 1, and follow in sequence to the abstract, manuscript and all 
other attachments. If you are unfamiliar with numbering, you can search HELP 
while in Microsoft Word, and it will show in detail how to number all pages.  
Title page: Title page must be submitted as a separate file. Include on the 
title page: (a) complete manuscript title; (b) authors' full names, highest academic 
degrees, and affiliations; (c) name and address for correspondence, including Fax 
number, telephone number, and E-mail address; (d) address for reprints if different 
from that of corresponding author (indicate whether reprints are available); and (e) 
all sources of support, including pharmaceutical and industry support, that require 
acknowledgment; (f) list three to five key words for indexing; (g) an abbreviated 
title of 55 characters or less used for the cover of the journal; (h) a running head 
title of 44 characters or less including spaces used for page headings on the pages 
in which your article is published.  
The title page must also include disclosure of funding received for this work from 
any of the following organizations: National Institutes of Health (NIH); Wellcome 
Trust; Howard Hughes Medical Institute (HHMI); and other(s).  
Structured abstract for Original Studies and Supplement Articles: Abstracts 
must be submitted as a separate file. Limit the abstract to 250 words. Do not cite 
references in the abstract. Limit the use of abbreviations and acronyms. Use the 
following subheads: Background, Methods, Results, and Conclusions (others may be 
added as needed).  
Unstructured abstract for Instructive Cases and Brief Reports: Abstract must 
be submitted as a separate file. Limit the abstract to 60 words. It must be factual 
and comprehensive. Limit the use of abbreviations and acronyms, and avoid 
general statements (e.g. "the significance of the results is discussed").  
Text: Organize the manuscript into four main headings, Introduction, Materials and 
Methods, Results, and Discussion. If a brand name is cited, supply the 
manufacturer's name and address (city and state/country).  
Abbreviations: For a list of standard abbreviations, consult the American Medical 
Association Manual of Style, 9th edition, or other standard sources. Write out the 
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full term for each abbreviation at its first use unless it is a standard unit of 
measure. Abbreviations are allowed only if used three times or more in text.  
References: The authors are responsible for the accuracy of the references. Key 
the references (double-spaced) at the end of the manuscript. Cite the references in 
text in the order of appearance, including those references cited in tables and figure 
legends at the chronological citation of the tables and figures in text. Cite 
unpublished data, such as papers submitted but not yet accepted for publication or 
personal communications, in parentheses in the text. If there are more than six 
authors, name only the first three authors and then use et al. Refer to the List of 
Journals Indexed in Index Medicus for abbreviations of journal names, or access the 
list at http://www.nlm.nih.gov/tsd/ serials/lji.html. Sample references are 
given below.  
Journal article 
1. Trujillo M, Correa N, Olsen K, et al. Cefprozil concentrations in middle ear fluid. 
Pediatr Infect Dis J. 2000;19:268 –270.  
Book chapter  
2. Grose C. Bacterial myositis and pyomyositis. In: Feigin RD, Cherry JD, eds. 
Textbook of Pediatric Infectious Diseases. 4th ed. Philadelphia: Lippincott Williams 
& Wilkins; 1998:704 – 708.  
Entire book  
3. Nelson JD, Bradley JS. Nelson's Pocket Book of Pediatric Antimicrobial Therapy. 
14th ed. Philadelphia: Lippincott Williams & Wilkins; 2000.  
Proceedings  
4. Harrigan PR, Dong W, Weber AE, et al. Highly mutated RT and protease 
[Abstract I-115]. In: 38th Interscience Conference on Antimicrobial Agents and 
Chemotherapy, San Diego, CA, September 24 to 27, 1998. Washington, DC: 
American Society for Microbiology; 1998.  
 
Online journals  
5. Friedman SA. Preeclampsia. Obstet Gynecol. [serial online]. January 
1988;71:22–37. Available from: BRS Information Technologies, McLean, VA. 
Accessed December 15, 1990.  
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World Wide Web  
6. Gostin LO. Drug use and HIV/AIDS [JAMA HIV/AIDS web site]. June 1, 1996. 
Available at: http://www.ama-assn.org/ special/hiv/ethics. Accessed June 26, 
1997.  
Figures: Cite figures consecutively in the text in the order in which they are 
discussed. All art should be created/scanned and saved and submitted as a TIFF 
(tagged image file format), EPS (encapsulated PostScript) file, or a PPT 
(PowerPoint) file. Line art must have a resolution of at least 1200 dpi (dots per 
inch), and electronic photographs (radiographs, CT scans, and so on) and scanned 
images must have a resolution of at least 300 dpi. If fonts are used in artwork, they 
must be converted to paths or outlines or they must be embedded in the files. 
Please note that artwork generated from office suite programs such as Corel Draw 
and MS Word and artwork downloaded from the Internet (JPEG or GIFF files) 
cannot be used. When preparing charts and graphs, authors are encouraged to use 
the same font (size and style of type) for all numbers and letters.  
Figure legends: Include legends for all figures. They should be brief and specific, 
and they should appear on a separate manuscript page after the references. 
Legends should be part of the manuscript file on the disk. Use scale markers in the 
image for electron micrographs, and indicate the type of stain used.  
Color figures: The journal accepts for publication color figures that enhance an 
article. Authors who submit color figures receive an estimate of the cost for color 
reproduction. If they decide not to pay for color reproduction, they can request that 
the figures be converted to black and white at no charge.  
Supplemental Digital Content  
Supplemental Digital Content (SDC): Authors may submit SDC via Editorial 
Manager to LWW journals that enhance their article's text to be considered for 
online posting. SDC may include standard media such as text documents, graphs, 
audio, video, etc. On the Attach Files page of the submission process, please select 
Supplemental Audio, Video, or Data for your uploaded file as the Submission Item. 
All SDC files should be uploaded as the author would like them presented in the 
final article. If an article with SDC is accepted, our production staff will create a URL 
with the SDC file. The URL will be placed in the call-out within the article. SDC files 
are not copyedited by LWW staff, they will be presented digitally as submitted. For 
SDC documents, any labels or legends should be included in the original SDC file 
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when submitted. For a list of all available file types and detailed instructions, please 
visit http://links.lww.com/A142.  
SDC Call-outs 
Supplemental Digital Content must be cited consecutively in the text of the 
submitted manuscript. Citations should include the type of material submitted 
(Audio, Figure, Table, etc.), be clearly labeled as "Supplemental Digital Content," 
include the sequential list number, and provide a description of the supplemental 
content. All descriptive text should be included in the call-out as it will not appear 
elsewhere in the article.  
Example:  
We performed many tests on the degrees of flexibility in the elbow (see Video, 
Supplemental Digital Content 1, which demonstrates elbow flexibility) and found 
our results inconclusive.  
List of Supplemental Digital Content 
A listing of Supplemental Digital Content must be submitted at the end of the 
manuscript file. Include the SDC number and file type of the Supplemental Digital 
Content. This text will be removed by our production staff and not be published. 
Example: 
Supplemental Digital Content 1. wmv  
SDC File Requirements 
All acceptable file types are permissible up to 10 MBs. For audio or video files 
greater than 10 MBs, authors should first query the journal office for approval. For 
a list of all available file types and detailed instructions, please visit 
http://links.lww.com/A142.  
Tables: Create tables using the table creating and editing feature of your word 
processing software (e.g., Word, WordPerfect). Do not use Excel or comparable 
spreadsheet programs. Provide a separate document for each table. Cite tables 
consecutively in the text, and number them in that order. Key each on a separate 
sheet, and include the table title, appropriate column heads, and explanatory 
legends (including definitions of any abbreviation not already defined in the text). 
Do not embed tables within the body of the manuscript. They should be self-
explanatory and should supplement, rather than duplicate, the material in the text. 
In each table, the genus of each genus-species must be written out at its first 
appearance.  
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Style: Stedman's Medical Dictionary (27th edition) and Merriam Webster's 
Collegiate Dictionary (10th edition) should be used as standard references. Refer to 
drugs and therapeutic agents by their accepted generic or chemical names, and do 
not abbreviate them. Use code numbers only when a generic name is not yet 
available. Capitalize the trade names of drugs and place them in parentheses after 
the generic names. To comply with trademark law, include the name and location 
(city and state/country) of the manufacturer of any drug, supply, or equipment 
mentioned in the manuscript. Use the metric system to express units of measure 
and degrees Celsius or degrees Fahrenheit consistently throughout the manuscript 
to express temperatures, and use SI units rather than conventional units. 
Abbreviate "liter" in such forms as "3 units/L" and "5 mL"; write out when used 
alone (10 liters; 0.5-liter gavage). See also Day RA, ed. How to Write and Publish a 
Scientific Paper. 5th ed. Phoenix, AZ: The Oryx Press, 1998.  
Brief Reports: Papers for this section should be no longer than 5–6 double-spaced 
typed manuscript pages (fewer than 1500 words), 10 references and 1 figure or 
table. Word count does not include Title Page or Unstructured Abstract.  
Letters to the Editors: Letters to the Editors should pertain to articles published 
within the Pediatric Infectious Disease Journal or highlight important new clinical or 
laboratory insights. Text should contain 500 words or fewer and less than 5 
references.  
Financial disclosure: In the cover letter, indicate all affiliations with or financial 
involvement in any organization or entity with a direct financial interest in the 
subject matter or materials of the research discussed in the manuscript (e.g. 
employment, consultancies, stock ownership). All such information will be held in 
confidence during the review process. Should the manuscript be accepted, the Chief 
Editors will discuss with the author the extent of disclosure appropriate for 
publication.  
After Acceptance  
Page proofs and corrections: Corresponding authors receive page proofs to 
check the copyedited and typeset article before publication. Portable document 
format (PDF) files of the typeset pages and support documents (e.g., reprint order 
form) are sent to the corresponding author by E-mail. Complete instructions are 
provided with the E-mail for downloading and printing the files and for faxing the 
corrected page proofs to the publisher. Those authors without an E-mail address 
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receive traditional page proofs. It is the author's responsibility to ensure that there 
are no errors in the proofs. Changes that have been made to conform to journal 
style stand if they do not alter the authors' meaning. Only the most critical changes 
to the accuracy of the content are made. Changes that are stylistic or are a 
reworking of previously accepted material are disallowed. The publisher reserves 
the right to deny any changes that do not affect the accuracy of the content. 
Authors may be charged for alterations to the proofs beyond those required to 
correct errors or to answer queries. Proofs must be checked carefully and returned 
within 24 to 48 hours of receipt, as requested in the cover letter accompanying the 
page proofs.  
Reprints: Authors receive a reprint order form with the page proofs that includes 
reprint costs. Reprint order forms should be returned to Author Reprint 
Department, Lippincott Williams & Wilkins, 351 West Camden Street, Baltimore, MD 
21201-2436. Reprints are normally shipped 6 to 8 weeks after publication of the 
issue in which the item appears. Contact the Author Reprint Department, Lippincott 
Williams & Wilkins, 351 W. Camden Street, Baltimore, MD 21201; Fax: 410-528-
4434; E-mail: reprintsgroup@lww.com with any questions.  
Permissions: For permission and/or rights to use content for which the copyright 
holder is LWW or the society, please go to the journal's website and after clicking 
on the relevant article, click on the "Request Permissions" link under the "Article 
Tools" box that appears on the righ  side of the page. Alternatively, send an e-mail 
to customercare@copyright.com.  
For Translation Rights & Licensing queries, contact Silvia Serra, Translations Rights, 
Licensing & Permissions Manager, Wolters Kluwer Health (Medical Research) Ltd, 
250 Waterloo Road, London SE1 8RD, UK. Phone: +44 (0) 207 981 
0600            +44 (0) 207 981 0600      . E-mail: silvia.serra@wolterskluwer.com  
For Special Projects and Reprints (U.S./Canada), contact Alan Moore, Director of 
Sales, Lippincott Williams & Wilkins, Two Commerce Square, 2001 Market Street, 
Philadelphia, PA 19103. Phone: 215-521-8638            215-521-8638      . E-mail: 
alan.moore@wolterskluwer.com  
For Special Projects and Reprints (non-U.S./Canada), contact Silvia Serra, 
Translations Rights, Licensing & Permissions Manager, Wolters Kluwer Health 
(Medical Research) Ltd, 250 Waterloo Road, London SE1 8RD, UK. Phone: +44 (0) 
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207 981 0600            +44 (0) 207 981 0600      . E-mail: 
silvia.serra@wolterskluwer.com  
Publisher's contact: Send corrected page proofs, color letters, and any other 
related materials to Emily Weisenreder, Emily.Weisenreder@wolterskluwer.com, 
410-528-4102            410-528-4102       (phone), 443-451-8147 (fax), or mail to 
Emily Weisenreder, Wolters Kluwer Health, 351 W. Camden Street, Baltimore, MD 
21201.  
Manuscript Checklist (before submission)  
• Cover letter  
• Title page (including conflicts of interest statement)  
• Abstract  
• Copyright Transfer & Disclosure form signed by all authors  
• Manuscript with figure legend if applicable  
• References double-spaced in US National Library of Medicine style  
• Corresponding author and E-mail address designated (in cover letter and on 
title page)  
• Permission to reproduce copyrighted materials or signed patient consent 
forms  
• Acknowledgments listed for grants and technical support  
• High quality print of electronic art . Tables created using table software 
features  
• Figures created/saved as TIFF, EPS, or PowerPoint files  
• At least 3 suggested reviewers  
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